Healthcare / Diagnostics & ResearchNasdaqCM
$22.53
-0.27 (-1.18%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $216000.00 · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$40M
P/E
N/A
•EV/EBITDA
25.4x
↑ROE
-2.5%
↓Gross Margin
44.5%
↓Debt/Equity
0.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+0.6%
FCF CAGR
-5.7%
FCF margin
1.5%
FCF / Net income
-0.99x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $24.0M · net income $-363000.0 · FCF $359000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $24.0M | $24.0M | $18.5M | $15.2M | $9.4M | $8.7M | $7.4M | $4.1M | $3.4M | $2.0M | $1.6M | $1.9M | $1.2M | $27.5M | $31.5M | $32.0M | $20.0M | $22.0M |
| Net Income | $-363000.00 | $-363000.00 | $-4.3M | $-5.9M | $-12.2M | $-8.5M | $-10.6M | $-13.2M | $-15.7M | $-20.7M | $-2.2M | $-33.0M | $-13.9M | $-16.0M | $-8.3M | $-9.8M | $-3.1M | $-1.9M |
| EBITDA | $1.5M | $1.5M | $-2.7M | $-4.3M | $-10.6M | $-8.5M | $-8.1M | $-9.9M | $-12.6M | $-14.8M | $-1.6M | $-8.4M | $-10.0M | $-13.0M | $-7.2M | $-871000.00 | $-2.9M | $-1.0M |
| EPS | -0.23 | -0.23 | -2.93 | -4.51 | -10.73 | -8.00 | -17.00 | — | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | 44.5% | 44.5% | 40.8% | 39.6% | 26.7% | 27.5% | 15.5% | 5.3% | 6.5% | 14.4% | 48.4% | -0.6% | -75.4% | 39.0% | 41.7% | 57.7% | 48.7% | 52.7% |
| Operating Margin | — | — | — | — | — | -110.5% | -123.1% | -268.5% | -403.5% | -763.0% | -110.0% | -462.4% | -852.3% | -57.2% | -30.2% | -9.3% | -18.0% | -8.6% |
| Net Margin | -1.5% | -1.5% | -23.1% | -38.5% | -129.7% | -97.9% | -142.6% | -323.4% | -455.2% | -1017.9% | -143.0% | -1708.3% | -1124.4% | -58.0% | -26.5% | -30.6% | -15.6% | -8.7% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.25 | 0.25 | 0.10 | 0.08 | 0.09 | 0.01 | 0.03 | 0.01 | 0.04 | 0.22 | -0.64 | 0.00 | 1.13 | 0.55 | 0.00 | 0.45 | 1.02 | — |
| Current Ratio | 1.61 | 1.61 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $359000.00 | $359000.00 | $216000.00 | $-3.7M | $-8.0M | $-7.3M | $-7.6M | $-9.2M | $-6.9M | $-6.8M | $-978000.00 | $-12.6M | $-13.8M | $-9.1M | $-11.1M | $-11000.00 | $-1.9M | $916000.00 |
| Returns | ||||||||||||||||||
| ROE | -2.5% | -2.5% | -35.5% | -40.6% | -74.9% | -34.7% | -75.0% | -100.3% | -256.3% | -158.9% | 34.5% | 1571.5% | -212.8% | -139.7% | -41.1% | -88.5% | -36.9% | -16.5% |
| Valuation | ||||||||||||||||||
| EV/EBITDA | 25.42 | 25.42 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 2.48 | 2.48 | 0.67 | 0.58 | 0.87 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 29.8% | 29.8% | 21.9% | 61.5% | — | 17.0% | 81.5% | 18.8% | 69.6% | 30.6% | -19.3% | 55.6% | -95.5% | -12.5% | -1.5% | 59.5% | -9.0% | — |
| EPS Growth | 92.2% | 92.2% | 35.0% | 58.0% | — | 52.9% | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+138.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.93 → -0.23
Residual
+138.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.